Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

400%(4 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_3

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

NCT01536418

completedphase_3

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

NCT01277666

terminatedphase_3

Open-Label Extension Study of GSK1605786A

NCT01318993

terminatedphase_3

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939

Clinical Trials (4)

Showing 4 of 4 trials

NCT01536418Phase 3

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Terminated

NCT01277666Phase 3

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Completed

NCT01318993Phase 3

Open-Label Extension Study of GSK1605786A

Terminated

NCT01316939Phase 3

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4